All In Biotech

Investigational drug · Phase 3

Empasiprubart

Also called: ARGX-117

Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multifocal Motor Neuropathy (MMN), Chronic Inflammatory Demyelinating Polyneuropathy, CIDP.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

9

9 still active

All registered trials

12

Any phase or sponsor naming "Empasiprubart"

First trial start

2023

Jan 18, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Empasiprubart", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Multifocal Motor Neuropathy (MMN)
  • Chronic Inflammatory Demyelinating Polyneuropathy
  • CIDP
  • AChR-Ab Seropositive Generalized Myasthenia Gravis
  • gMG
  • Delayed Graft Function
  • MMN
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
  • Myasthenia Gravis

Approved drugs for the same conditions: Myasthenia gravis · Neurology

Largest trials

Live from ClinicalTrials.gov: studies naming "Empasiprubart" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 7 on PubMed

Also in development for Multifocal Motor Neuropathy (MMN)

  • TAK-771Phase 32 trials

    Takeda · Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), Primary Immunodeficiency Diseases (PID)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from argenx.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.